Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 25
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
ImmunityBio Inc
IBRX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$8.22
-0.09
-1.08%
Dern. MÀJ: Oct 23, 7:37 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
ImmunityBio Financials
ImmunityBio (IBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the
Benzinga Newsdesk
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum
ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and updated bladder cancer treatment guidelines.
Vandana Singh
PRO
UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent increase over losses of $(0.10) per share from the
Benzinga Newsdesk
PRO
ImmunityBio Q1 EPS $(0.62) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.07) by 785.71 percent. This is a 313.33 percent decrease over losses of $(0.15) per share from
Benzinga Newsdesk
Why Is ImmunityBio Stock Rallying Thursday?
ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning prompts review of promotional claims.
Vandana Singh
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio stock climbs after Anktiva sales surge 750%, revenue beats estimates, and new Saudi partnership fuels growth.
Vandana Singh
